TY - JOUR
T1 - Immunogenicity of hepatitis B vaccine in preterm infants
AU - Blondheim, Orna
AU - Bader, David
AU - Abend, Martha
AU - Peniakov, Marina
AU - Reich, Danny
AU - Potesman, I.
AU - Handsher, Rachel
AU - Gidoni, Ifat
AU - Linder, Nehama
PY - 1998
Y1 - 1998
N2 - Aim - To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth. Method - The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test. Results - A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p=NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p<0.03). Conclusion - Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.
AB - Aim - To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth. Method - The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test. Results - A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p=NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p<0.03). Conclusion - Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.
KW - Hepatitis B vaccine
KW - Immune response
UR - http://www.scopus.com/inward/record.url?scp=0031773158&partnerID=8YFLogxK
U2 - 10.1136/fn.79.3.F206
DO - 10.1136/fn.79.3.F206
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0031773158
SN - 1359-2998
VL - 79
SP - F206-F208
JO - Archives of Disease in Childhood: Fetal and Neonatal Edition
JF - Archives of Disease in Childhood: Fetal and Neonatal Edition
IS - 3
ER -